Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently spreading worldwide. The pandemic has already had significant adverse effects on human civilization, the environment, and the ecosystem at national and global levels. Moreover, the various sectors of the food production chain, particularly agriculture and livestock, have also been significantly affected in terms of production sustainability and economic losses. The global pandemic has already resulted in a sharp drop in meat, milk, and egg production. Restrictions of movement at national and international levels, implemented as a part of control strategies by public health sectors, have negatively impacted business related to the supply of raw materials for livestock farmers and farm outputs, veterinary services, farmworkers, and animal welfare. This review highlights the significant impacts of COVID-19 on the sustainability of livestock performance, welfare on a global scale, and strategies for mitigating these adverse effects.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483476PMC
http://dx.doi.org/10.1007/s11250-022-03256-xDOI Listing

Publication Analysis

Top Keywords

covid-19 sustainability
8
sustainability livestock
8
livestock performance
8
performance welfare
8
welfare global
8
global scale
8
adverse effects
8
influence covid-19
4
livestock
4
global
4

Similar Publications

What happened next? A survey of review clients evaluating impacts of rapid reviews.

J Clin Epidemiol

January 2025

National Collaborating Centre for Methods and Tools,175 Longwood Rd. S., Suite 210A, Hamilton, ON, L8P 0A1; School of Nursing, McMaster University, Health Sciences Centre, 2J20, 1280 Main St W, Hamilton, ON, L8S 4K1, Canada.

Introduction: End-user evaluation of the impact of evidence syntheses is critical to demonstrating value. This study presents results of a survey evaluating the impact of rapid reviews undertaken by two teams based in Melbourne, Australia and Hamilton, Canada.

Methods: Clients were invited to participate in a short, written survey following delivery of a rapid review.

View Article and Find Full Text PDF

The first five years of implementing Missouri's medication first approach to opioid use disorder treatment: Plateaus, regressions, and underbellies of progress.

J Subst Use Addict Treat

January 2025

University of Missouri-St. Louis, Addiction Science, Missouri Institute of Mental Health, 1 University Blvd., Benton Hall, Room 206, St. Louis, MO 63121, USA.

Introduction: Missouri's Medication First ("MedFirst") approach promotes same-day and long-term low-threshold access to medications for opioid use disorder (MOUD). Since 2017, Missouri's SAMHSA-funded State Targeted and State Opioid Response (STR/SOR) grants have supported MedFirst services (both medical and psychosocial) for uninsured individuals with opioid use disorder at state-contracted treatment programs. Though MedFirst demonstrated early success, results - with attention to possible racial disparities - must be revisited after five years of implementation.

View Article and Find Full Text PDF

Rapid emergence, transmission, and evolution of KPC and NDM coproducing carbapenem-resistant Klebsiella pneumoniae.

Microbiol Res

January 2025

Research Institute of General Surgery, Jinling Hospital, the Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Electronic address:

Article Synopsis
  • Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a major clinical concern due to limited treatment options, worsened by the emergence of KPC and NDM co-producing strains.
  • A study identified 15 strains involved in an outbreak affecting 10 patients between October 2020 and May 2021, characterized by a highly stable hybrid plasmid co-harboring resistance genes.
  • Global genomic analysis of 327 KPC-NDM-CRKP genomes revealed potential transmission events during the COVID-19 period, highlighting the urgent public health threat posed by these resistant strains.
View Article and Find Full Text PDF

Objectives: Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL-17A, previously demonstrated efficacy and was well tolerated to 1 year in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA). Here, we report bimekizumab safety and efficacy to 2 years.

Methods: Patients completing week 52 in the phase 3 studies BE MOBILE 1 (nr-axSpA; NCT03928704) and 2 (r‑axSpA; NCT03928743) were eligible for an ongoing open‑label extension (OLE; NCT04436640).

View Article and Find Full Text PDF

Background: Implementation and hybrid effectiveness-implementation trials aspire to speed the translation of science into practice by generating crucial evidence for improving the uptake of effective health interventions. By design, they pose unique recruitment and retention challenges due to their aims, units of analysis, and sampling plans, which typically require many clinical sites (i.e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!